ADVANCING GENE THERAPY FOR RARE DISEASE
AavantiBio, Inc. is a clinical-stage biotechnology company developing gene therapy for the debilitating neuromuscular disease known as Friedreich’s Ataxia (FA).
After working for several years to research the disease and getting to meet some of the amazing members of the FA community, founders Dr. Barry Byrne and Dr. Manuela Corti decided that they wanted to take their research to the next level to create the first effective treatment for FA.
Friedreich's Ataxia is a neuromuscular disease that affects movement, coordination and the heart.
AavantiBio's research focuses on cutting edge gene therapy for Friedreich's Ataxia.
See how you can make a difference in the fight to create a treatment for FA.